Zimbabwe in line to reach antiretroviral treatment target, health official says

Zimbabwe could meet its target of providing 140,000 HIV-positive people with access to no-cost antiretroviral drugs by the end of the year, Owen Mugurungi, head of the Zimbabwean government's HIV/AIDS unit, said on Tuesday at a two-day workshop on drug access issues in the country, the Herald/AllAfrica.com reports (Herald/AllAfrica.com, 10/26).

The country's efforts to increase access to antiretrovirals have been delayed by a shortage of foreign currency, which has increased poverty levels and raised inflation by 3,700%. More than 3,000 people die of AIDS-related illnesses weekly in the country, and 70% of hospital admissions in Zimbabwe are HIV/AIDS-related. According to Zimbabwe Health and Child Welfare Minister David Parirenyatwa, at least 300,000 people living with HIV/AIDS in the country are in need of antiretrovirals (Kaiser Daily HIV/AIDS Report, 9/12). According to Mugurungi, about 90,000 HIV-positive people have access to no-cost antiretrovirals under the government's treatment program.

"More than 80% of our target population" already has antiretroviral access, and if the country doubles its "efforts in the next two months, that means [Zimbabwe] might surpass" the 140,000 target, Mugurungi said. The country is among other African nations that believe a 100% universal access to antiretrovirals is unrealistic, Mugurungi said, adding that Zimbabwe instead aims to provide 75% of HIV-positive people with treatment access. Raymond Yekeye, operations director for the National AIDS Council, agreed and said that Zimbabwe now is looking to fulfill district-level treatment targets (Herald/AllAfrica.com, 10/26).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding access to GLP-1 weight-loss drugs could save thousands of lives